Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature

go back to reference Dalal S, Del Fabbro E, Bruera E (2006) Symptom control in palliative care: part I—oncology as a paradigmatic example. J Palliat Med 9:391–408CrossRefPubMed Dalal S, Del Fabbro E, Bruera E (2006) Symptom control in palliative care: part I—oncology as a paradigmatic example. J Palliat Med 9:391–408CrossRefPubMed

go back to reference Zaider T, Kissane D (2009) The assessment and management of family distress during palliative care. Curr Opin Support Palliat Care 3:67–71CrossRefPubMedPubMedCentral Zaider T, Kissane D (2009) The assessment and management of family distress during palliative care. Curr Opin Support Palliat Care 3:67–71CrossRefPubMedPubMedCentral

go back to reference World Health Organization: National Cancer Control Programmes: policies and managerial guidelines. http://www.who.int/cancer/palliative/definition/en/ World Health Organization: National Cancer Control Programmes: policies and managerial guidelines. http://​www.​who.​int/​cancer/​palliative/​definition/​en/​

go back to reference Mount BM (1976) The problem of caring for the dying in a general hospital; the palliative care unit as a possible solution. Can Med Assoc J 115:119–121PubMedPubMedCentral Mount BM (1976) The problem of caring for the dying in a general hospital; the palliative care unit as a possible solution. Can Med Assoc J 115:119–121PubMedPubMedCentral

go back to reference Bruera E, Sweeney C (2002) Palliative care models: international perspective. J Palliat Med 5:319–327CrossRefPubMed Bruera E, Sweeney C (2002) Palliative care models: international perspective. J Palliat Med 5:319–327CrossRefPubMed

go back to reference Higginson IJ, Finlay I, Goodwin DM, Cook AM, Hood K, Edwards AGK, Douglas HR, Norman CE (2002) Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manag 23:96–106CrossRef Higginson IJ, Finlay I, Goodwin DM, Cook AM, Hood K, Edwards AGK, Douglas HR, Norman CE (2002) Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manag 23:96–106CrossRef

go back to reference Higginson IJ, Finlay IG, Goodwin DM, Hood K, Edwards AGK, Cook A, Douglas HR, Normand CE (2003) Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Mange 25:150–168CrossRef Higginson IJ, Finlay IG, Goodwin DM, Hood K, Edwards AGK, Cook A, Douglas HR, Normand CE (2003) Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Mange 25:150–168CrossRef

go back to reference Hui D, Elsayem A, De la Cruz M et al (2010) Availability and integration of palliative care at US cancer centers. JAMA 303:1054–1061CrossRefPubMedPubMedCentral Hui D, Elsayem A, De la Cruz M et al (2010) Availability and integration of palliative care at US cancer centers. JAMA 303:1054–1061CrossRefPubMedPubMedCentral

go back to reference Hui D, Elsayem A, Palla S, de la Cruz M, Li Z, Yennurajalingam S, Bruera E (2010) Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med 13:49–57CrossRefPubMedPubMedCentral Hui D, Elsayem A, Palla S, de la Cruz M, Li Z, Yennurajalingam S, Bruera E (2010) Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med 13:49–57CrossRefPubMedPubMedCentral

go back to reference Braiteh F, El Osta B, Palmer JL et al (2007) Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center. J Palliat Med 10:948–955CrossRefPubMed Braiteh F, El Osta B, Palmer JL et al (2007) Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center. J Palliat Med 10:948–955CrossRefPubMed

go back to reference Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manag 27:481–491CrossRef Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manag 27:481–491CrossRef

go back to reference Osta Be PJL, Paraskevopoulos T et al (2008) Interval between first palliative consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 11:51–57CrossRefPubMed Osta Be PJL, Paraskevopoulos T et al (2008) Interval between first palliative consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 11:51–57CrossRefPubMed

go back to reference Cheng WW, Willey J, Palmer JL, Zhang T, Bruera E (2005) Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med 8:1025–1032CrossRefPubMed Cheng WW, Willey J, Palmer JL, Zhang T, Bruera E (2005) Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med 8:1025–1032CrossRefPubMed

go back to reference Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y (2005) Late referrals to specialized palliative care service in Japan. J Clin Oncol 23:2637–2644CrossRefPubMed Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y (2005) Late referrals to specialized palliative care service in Japan. J Clin Oncol 23:2637–2644CrossRefPubMed

go back to reference Morita T, Miyashita M, Tsuneto S, Sato K, Shima Y (2009) Late referrals to palliative care units in Japan: nationwide follow-up survey and effects of palliative care team involvement after the cancer control act. J Pain Symptom Manag 38:191–196CrossRef Morita T, Miyashita M, Tsuneto S, Sato K, Shima Y (2009) Late referrals to palliative care units in Japan: nationwide follow-up survey and effects of palliative care team involvement after the cancer control act. J Pain Symptom Manag 38:191–196CrossRef

go back to reference Bakitas M, Lyons KD, Hegel MT, Balan S, Barnett KN, Brokaw FC, Byock IR, Hull JG, Li Z, Mckinstry E, Seville JL, Ahles TA (2009) The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions. Palliat Support Care 7:75–86CrossRefPubMedPubMedCentral Bakitas M, Lyons KD, Hegel MT, Balan S, Barnett KN, Brokaw FC, Byock IR, Hull JG, Li Z, Mckinstry E, Seville JL, Ahles TA (2009) The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions. Palliat Support Care 7:75–86CrossRefPubMedPubMedCentral

go back to reference Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, Prigerson HG (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300:1665–1673CrossRefPubMedPubMedCentral Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, Prigerson HG (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300:1665–1673CrossRefPubMedPubMedCentral

go back to reference Bruera E, Hui D (2010) Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. J Clin Oncol 28(25):4013–4017CrossRefPubMed Bruera E, Hui D (2010) Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. J Clin Oncol 28(25):4013–4017CrossRefPubMed

go back to reference Freireich EJ, Kurzrock R (2009) The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol 27:304–306CrossRefPubMed Freireich EJ, Kurzrock R (2009) The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol 27:304–306CrossRefPubMed

go back to reference Hui D, Elsayem A, Li Z, de la Cruz M, Palmer JL, Bruera E (2010) Antineopalstic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer 116:2036–2043CrossRefPubMedPubMedCentral Hui D, Elsayem A, Li Z, de la Cruz M, Palmer JL, Bruera E (2010) Antineopalstic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model. Cancer 116:2036–2043CrossRefPubMedPubMedCentral

go back to reference Hui D, Parsons HA, Nguywen L et al (2010) Timing of palliative care referral and symptom burden in phase I cancer patients: a retrospective cohort study. Cancer 116:4402–4409CrossRefPubMedPubMedCentral Hui D, Parsons HA, Nguywen L et al (2010) Timing of palliative care referral and symptom burden in phase I cancer patients: a retrospective cohort study. Cancer 116:4402–4409CrossRefPubMedPubMedCentral

go back to reference Fadul N, Elsayem A, Palmer JL, del Fabbro E, Swint K, Li Z, Poulter V, Bruera E (2009) Supportive versus palliative care: what’s in a name?—a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer 115:2013–2021CrossRefPubMed Fadul N, Elsayem A, Palmer JL, del Fabbro E, Swint K, Li Z, Poulter V, Bruera E (2009) Supportive versus palliative care: what’s in a name?—a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer 115:2013–2021CrossRefPubMed

go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249CrossRefPubMed

go back to reference Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed

go back to reference Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–903CrossRefPubMed Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–903CrossRefPubMed

go back to reference Hopwood P, Stephens RJ (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 71:633–636CrossRefPubMedPubMedCentral Hopwood P, Stephens RJ (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 71:633–636CrossRefPubMedPubMedCentral

go back to reference Lutz S, Norrel R, Bertucio C et al (2001) Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the lung cancer symptom scale in a community hospital. J Palliat Med 4:157–165CrossRefPubMed Lutz S, Norrel R, Bertucio C et al (2001) Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the lung cancer symptom scale in a community hospital. J Palliat Med 4:157–165CrossRefPubMed

go back to reference Mok TS (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 36:947–957CrossRef Mok TS (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 36:947–957CrossRef

go back to reference Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMed Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMed

go back to reference Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394CrossRefPubMed Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394CrossRefPubMed

go back to reference Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators (2014) PROFILE 1014 investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefPubMed Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators (2014) PROFILE 1014 investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefPubMed

go back to reference Mazieres J, Zalcman G, Crinò L et al (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33:992–999CrossRefPubMed Mazieres J, Zalcman G, Crinò L et al (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33:992–999CrossRefPubMed

go back to reference Sadiq AA, Salgia R (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089–1096CrossRefPubMedPubMedCentral Sadiq AA, Salgia R (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089–1096CrossRefPubMedPubMedCentral

go back to reference Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral

go back to reference Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral

go back to reference Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet 387:1540–1550CrossRefPubMed Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet 387:1540–1550CrossRefPubMed

go back to reference Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ (2007) Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol 25(17):2377–2382CrossRefPubMed Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ (2007) Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol 25(17):2377–2382CrossRefPubMed

go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34

go back to reference Zimmermann C, Swami N, Kryzanowska M et al (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383:1721–1730CrossRefPubMed Zimmermann C, Swami N, Kryzanowska M et al (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383:1721–1730CrossRefPubMed

go back to reference Nieder C, Tollali T, Haukland E et al (2016) Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer. Support Care Cancer 24:4385–4391CrossRefPubMed Nieder C, Tollali T, Haukland E et al (2016) Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer. Support Care Cancer 24:4385–4391CrossRefPubMed

go back to reference King JD, Eikhoff J, Traynor A et al (2016) Integrated onco-palliative care associated with prolonged survival compared to standard care for patients with advanced lung cancer: a retrospective review. J Pain Symptom Manag 51(6):1027–1032CrossRef King JD, Eikhoff J, Traynor A et al (2016) Integrated onco-palliative care associated with prolonged survival compared to standard care for patients with advanced lung cancer: a retrospective review. J Pain Symptom Manag 51(6):1027–1032CrossRef

go back to reference Temel JS, Greer JA, El-Jawahri A et al (2017) Effects of early palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 35(8):834–841CrossRefPubMed Temel JS, Greer JA, El-Jawahri A et al (2017) Effects of early palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 35(8):834–841CrossRefPubMed

go back to reference Sabesan S, Piliouras P (2009) Disparity in cancer survival between urban and rural patients—how can clinicians help reduce it? Rural Remote Health 9:1146–1150PubMed Sabesan S, Piliouras P (2009) Disparity in cancer survival between urban and rural patients—how can clinicians help reduce it? Rural Remote Health 9:1146–1150PubMed

go back to reference Ambroggi M, Biasini C, Del Giovane C et al (2015) Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 20(12):1378–1385CrossRefPubMedPubMedCentral Ambroggi M, Biasini C, Del Giovane C et al (2015) Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 20(12):1378–1385CrossRefPubMedPubMedCentral

go back to reference Zagonel V, Franciosi V, Brunello A, Biasco G, Broglia C, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltoni M, Marchetti P, Massa E, Mastromauro C, Melotti B, Meriggi F, Nacci A, Pavese I, Piva E, Quirino M, Roselli M, Sacco C, Tonini G, Trentin L, Ucci G, Labianca R, Gori S, Pinto C, Cascinu S, AIOM Simultaneous & Continuous Care (SCC), Task Force: ESMO Italian DCs (2017) Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (simultaneous care). Tumori 103(1):9–14CrossRefPubMed Zagonel V, Franciosi V, Brunello A, Biasco G, Broglia C, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltoni M, Marchetti P, Massa E, Mastromauro C, Melotti B, Meriggi F, Nacci A, Pavese I, Piva E, Quirino M, Roselli M, Sacco C, Tonini G, Trentin L, Ucci G, Labianca R, Gori S, Pinto C, Cascinu S, AIOM Simultaneous & Continuous Care (SCC), Task Force: ESMO Italian DCs (2017) Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (simultaneous care). Tumori 103(1):9–14CrossRefPubMed